Metamphetamine use disorder. Other stimulant dependence, uncomplicated
Conditions
Interventions
Intervention 1: Intervention group: Half of participants will be treated by desipramine (Exir pharmaceutical company) at the dose of 50 mg once per day orally and gradually increasing to 100 mg once
Sponsors
Mental Health Research Center
Eligibility
Sex/Gender
Male
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Age between 18 to 50 Current diagnosis of methamphetamine use disorder based on DSM IV-TR criteria Positive urine test for methamphetamine prior to study entry Male gender
Exclusion criteria
Exclusion criteria: Having conditions known to be deteriorated following desipramine use such as obesity, liver diseases, and cardiovascular diseases Taking antidepressants of any class in during the two weeks prior to entering the study Taking medications with potential effect on methamphetamine craving (i.e. modafinil, bupropion, naltrexone, N-acetylcysteine) Taking medications known to adversely interact with desipramine Serious mood disorders, suicidal ideation, and psychotic disorders requiring hospitalization Comorbid medical conditions, as revealed by history review, physical exam, or laboratory results of blood chemistry test and liver profile Incidence of a life-threatening side effect following medication use (i.e. liver failure, pancreatitis, hepatic encephalopathy, thrombocytopenia, leucopenia) Medication intolerance Use of other substances (except methadone maintenance therapy, nicotine, cannabis, and morphine) confirmed by a toxicology screen Currently (during a month prior to study) in treatment for methamphetamine use Having DSM IV-TR diagnosis of other substance use disorders in the past year No longer willing to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Metamphemine craving. Timepoint: before intervention, at the end of each month after intervention until 4 months (0-1-2-3-4). Method of measurement: Cocaine Craving Questionnaire-Brief.;Positive urine toxicology test for methamphetamine. Timepoint: Before intervention, at the end of each month after intervention until 4 months (0-1-2-3-4). Method of measurement: Urine toxicology test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug Side Effects. Timepoint: Before intervention and at the end of each month after intervention until 4 months (0-1-2-3-4). Method of measurement: Side effects questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Hamidreza Ahmadkhaniha
Iran University of Medical Sciences
Outcome results
None listed